Leading medical device company Medtronic has reported real-world clinical outcomes for its MiniMed 670G insulin delivery system.
The new report is based on nearly 8 million patient days. It showed an average 'Time in Range' of 71 per cent across all age groups.
The MiniMed 670G system automates and personalises the delivery of basal insulin 24 hours a day.
"The consistent data across a large sample in the real-world illustrates the positive outcomes with the MiniMed 670G in an uncontrolled environment," said Dr Satish Garg, Professor of Medicine and Pediatrics and Director of the Adult Diabetes Division of Barbara Davis Center of the University of Colorado.
"Since the launch of the system in 2017, there has been a growing body of data that shows that the system consistently improves Time in Range in majority of the patients who successfully are able to stay in the Auto Mode surpassing that of other commercially available methods of Type 1 diabetes management.
"These observations in a real-world setting of what was initially observed in the controlled pivotal trial of the system are impressive. The MiniMed 670G represents the highest standard of care for diabetes today."
“Clinical consensus about Time in Range is that the goal of effective diabetes management is to have a person be in the recommended range of 70-180 mg/dL for at least 70 per cent of time. This may increase the likelihood that short and long-term complications of this chronic disease can be avoided,” said Dr Robert Vigersky, chief medical officer for the Diabetes Group at Medtronic.
“The high number of adult patients reaching and surpassing this Time in Range goal illustrates the strong positive outcomes that the MiniMed 670G system can drive. Improved Time in Range is also seen in children as young as 7 who face unique challenges with maintaining control due to a variety of factors including increased insulin sensitivity and cognitive, behavioural, and social-emotional development during this phase of life.”
According to Medtronic, on average, people using the MiniMed 670G system experienced 2.3 additional hours of Time in Range per day compared to people not using these features, representing more than 35 additional days a year that a person with diabetes is spending in the target glucose range.